Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 12/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 8/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | TERT | O14746 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13887116 | 1.00 | DPP4 (0.44) | DPP4DPP8DPP9HDAC7HDAC8 | |
| SCHEMBL245069 | 1.00 | DPP4 (0.44) | DPP4DPP8DPP9HDAC7HDAC8 | |
| SCHEMBL9650376 | 0.82 | DPP4 (0.44) | DPP4DPP8DPP9CA1CA2 | |
| SCHEMBL8122592 | 0.82 | DPP4 (0.44) | DPP4DPP8DPP9TERTDPP7 | |
| SCHEMBL15731847 | 0.82 | DPP4 (0.44) | DPP4DPP8DPP9TERTDPP7 | |
| SCHEMBL8122591 | 0.82 | DPP4 (0.44) | DPP4DPP8DPP9TERTDPP7 | |
| SCHEMBL9650387 | 0.82 | DPP4 (0.44) | DPP4DPP8DPP9CA1CA2 | |
| SCHEMBL6686776 | 0.82 | DPP4 (0.44) | DPP4DPP8DPP9TERTDPP7 | |
| SCHEMBL9969913 | 0.82 | DPP4 (0.44) | DPP4DPP8DPP9TERTDPP7 | |
| SCHEMBL3661089 | 0.82 | DPP4 (0.44) | DPP4DPP8DPP9CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 450 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3009504-B1 | MICROORGANISM PRODUCING L-ISOLEUCINE AND METHOD FOR PREPARING L-ISOLEUCINE USING THE SAME | CJ CHEILJEDANG CORP (KR) | 2020-12-02 | — | — | EP | claimed |
| US-20160145699-A1 | L-ISOLEUCINE-PRODUCING MICROORGANISM AND METHOD OF PRODUCING L-ISOLEUCINE USING THE SAME | CJ CHEILJEDANG CORPORATION (KR) | 2016-05-26 | — | — | US | claimed |
| EP-3009504-A1 | MICROORGANISM PRODUCING L-ISOLEUCINE AND METHOD FOR PREPARING L-ISOLEUCINE USING SAME | Cj Cheiljedang Corporation (KR) | 2016-04-20 | — | — | EP | claimed |
| WO-2014200126-A1 | MICROORGANISM PRODUCING L-ISOLEUCINE AND METHOD FOR PREPARING L-ISOLEUCINE USING SAME | 씨제이제일제당 (주) (KR) | 2014-12-18 | — | — | WO | claimed |
| US-20020076393-A1 | Method for stimulation of defensin production | MAGAININ PHARMACEUTICALS, INC. | 2002-06-20 | — | — | US | claimed |
| WO-2001068085-A1 | A METHOD FOR STIMULATION OF DEFENSIN PRODUCTION | GENAERA CORPORATION (US) | 2001-09-20 | — | — | WO | claimed |
| EP-1093364-A1 | A METHOD FOR STIMULATION OF DEFENSIN PRODUCTION BY EXPOSURE TO ISOLEUCIN | MAGAININ PHARMACEUTICALS INC. (US) | 2001-04-25 | — | — | EP | claimed |
| WO-1999059574-A1 | A METHOD FOR STIMULATION OF DEFENSIN PRODUCTION BY EXPOSURE TO ISOLEUCIN | MAGAININ PHARMACEUTICALS, INC. (US) | 1999-11-25 | — | — | WO | claimed |
| EP-0542487-A2 | Process for producing L-isoleucine | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1993-05-19 | — | — | EP | claimed |
| JP-3112479-A | — | — | None | — | — | JP | disclosed |
| JP-62198396-A | — | — | None | — | — | JP | disclosed |
| US-12590128-B2 | Acetohydroxy acid synthase variant and microorganism including the same | CJ CHEILJEDANG CORPORATION (KR) | 2026-03-31 | — | — | US | disclosed |
| US-12385074-B2 | Method of producing L-amino acids | AJINOMOTO CO., INC. (JP) | 2025-08-12 | — | — | US | disclosed |
| EP-4505875-A1 | METHOD FOR CONTROLLING PARASITIC PLANTS | AJINOMOTO CO., INC. (JP) | 2025-02-12 | — | — | EP | disclosed |
| EP-0131171-A1 | Coryneform bacteria carrying recombinant plasmids and their use in the fermentative production of l-threonine and l-isoleucine | AJINOMOTO CO., INC. (JP) | 1985-01-16 | — | — | EP | disclosed |
| US-4442208-A | GENETICALLY ENGINEERED CORYNEBACTERIUM OR BREVIBACTERIUM | AJINOMOTO CO., INC. (JP) | 1984-04-10 | — | — | US | disclosed |
| US-4411991-A | MIXTURES, MICROORGANISMS, CARBOHYDRATES, LACTIC ACID, ONE STEP, AEROBIC | KANEGAFUCHI CHEMICAL INDUSTRY COMPANY, LIMITED (JP) | 1983-10-25 | — | — | US | disclosed |
| EP-0071023-A2 | Method for producing L-isoleucine by fermentation | AJINOMOTO CO., INC. (JP) | 1983-02-09 | — | — | EP | disclosed |
| US-4329427-A | BREVIBACTERIUM CULTURE | W. R. GRACE & CO. (US) | 1982-05-11 | — | — | US | disclosed |
| US-4183786-A | FROM GYLCINE BY CULTURING MUTANT OF NOCARDIA | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1980-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12590128-B2 | Acetohydroxy acid synthase variant and microorganism including the same | ASNS, BCAT1, AARS1 | DPP4 1644/4885DPP8 1092/4885DPP9 1757/4885 |
| US-20020076393-A1 | Method for stimulation of defensin production | STING1, IFNG, TLR5 | DPP4 420/4885DPP8 874/4885DPP9 373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.